Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BS-006 by Wuhan Binhui Biopharmaceutical for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
BS-006 is under clinical development by Wuhan Binhui Biopharmaceutical and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC)....
BS-006 by Wuhan Binhui Biopharmaceutical for Solid Tumor: Likelihood of Approval
BS-006 is under clinical development by Wuhan Binhui Biopharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData,...
BS-006 by Wuhan Binhui Biopharmaceutical for Metastatic Melanoma: Likelihood of Approval
BS-006 is under clinical development by Wuhan Binhui Biopharmaceutical and currently in Phase I for Metastatic Melanoma. According to GlobalData,...
BS-006 by Wuhan Binhui Biopharmaceutical for Breast Cancer: Likelihood of Approval
BS-006 is under clinical development by Wuhan Binhui Biopharmaceutical and currently in Phase I for Breast Cancer. According to GlobalData,...